Chinese pharmaceutical companies have emerged as a new force in global healthcare innovation, forging a unique path through R&D breakthroughs, local strategic expansion, and AI-driven advancements. Amidst these dynamic developments, the recent CEIBS MBA Healthcare Industry Forum 2025 brought together distinguished leaders from the healthcare industry, policy scholars, think tank experts, and executives from cutting-edge Chinese and international enterprises to share insights on industry trends, innovation strategies, and new opportunities in artificial intelligence.

Learn more about the CEIBS MBA programme, recently ranked #1 in Asia in the Financial Times’ 2024 Global MBA Ranking for the ninth consecutive year, here.